

Robert Marcus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11668936/publications.pdf>

Version: 2024-02-01

81
papers

4,173
citations

257357

24
h-index

149623

56
g-index

85
all docs

85
docs citations

85
times ranked

3955
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial. <i>HemaSphere</i> , 2022, 6, e699.	1.2	9
2	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	0.6	56
3	End of induction positron emission tomography complete response (PET- \leq CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma. <i>British Journal of Haematology</i> , 2022, 198, 333-337.	1.2	2
4	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021, 5, 1737-1745.	2.5	4
5	Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. <i>Blood</i> , 2021, 137, 2704-2707.	0.6	21
6	An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial. <i>Blood</i> , 2021, 138, 39-39.	0.6	1
7	The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells. <i>Haematologica</i> , 2020, 105, 1593-1603.	1.7	28
8	Follicular Lymphoma Evaluation Index (<sc>FLEX</sc>): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. <i>American Journal of Hematology</i> , 2020, 95, 1503-1510.	2.0	26
9	Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. <i>Blood Advances</i> , 2020, 4, 1589-1593.	2.5	16
10	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4634-4643.	3.2	49
11	Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1495-1506.	1.1	7
12	Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. <i>Haematologica</i> , 2019, 104, 1202-1208.	1.7	64
13	A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group. <i>Blood</i> , 2019, 134, 2812-2812.	0.6	0
14	A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation. <i>European Journal of Haematology</i> , 2018, 100, 98-103.	1.1	6
15	New Treatment Options in Advanced Stage Follicular Lymphoma. <i>HemaSphere</i> , 2018, 2, e156.	1.2	1
16	First-Line Management of Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S83-S85.	0.2	0
17	A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial. <i>Blood</i> , 2018, 132, 2872-2872.	0.6	3
18	Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials. <i>Blood</i> , 2018, 132, 1605-1605.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study. <i>Blood</i> , 2018, 132, 1597-1597.	0.6	13
20	Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. <i>Blood</i> , 2018, 132, 396-396.	0.6	23
21	Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study. <i>Blood</i> , 2018, 132, 2882-2882.	0.6	17
22	Relationship between MRD and PET responses and PFS in previously untreated follicular lymphoma in the GALLIUM trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 7557-7557.	0.8	9
23	Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2051-2056.	0.6	7
24	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 552-560.	0.8	87
25	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1331-1344.	13.9	575
26	Non-Hodgkin lymphoma of the cauda equina: a rare entity. <i>British Journal of Neurosurgery</i> , 2017, 31, 734-735.	0.4	2
27	Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials. <i>Blood</i> , 2017, 130, 727-727.	0.6	2
28	Obinutuzumab Treatment of Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2605-2606.	13.9	4
29	<sc>ALK</sc>-positive large B-cell lymphoma with strong <sc>CD</sc>30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib. <i>Histopathology</i> , 2016, 69, 880-882.	1.6	12
30	Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. <i>Aids</i> , 2015, 29, 903-910.	1.0	29
31	Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 111-117.	2.0	27
32	<sc>B</sc>-ritish <sc>HIV</sc> Association guidelines for <sc>HIV</sc>-associated malignancies 2014. <i>HIV Medicine</i> , 2014, 15, 1-92.	1.0	67
33	Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. <i>Leukemia Research</i> , 2014, 38, 737-743.	0.4	7
34	Multiparameter Microscopy Analysis of the Follicular Lymphoma Microenvironment and Normal Germinal Centers: In Vivo evidence That Follicular Helper T Cells Form Synapses with Neoplastic B Cells and Are Associated with Proliferation and Expression of Activation Induced Cytidine Deaminase. <i>Blood</i> , 2014, 124, 144-144.	0.6	0
35	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
36	Polymorphisms in ABCB11 and ATP8B1 Associated with Development of Severe Intrahepatic Cholestasis in Hodgkin's Lymphoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 159-161.	0.4	14

#	ARTICLE	IF	CITATIONS
37	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013, 122, 1137-1143.	0.6	120
38	An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8614-TPS8614.	0.8	2
39	Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000). <i>Blood</i> , 2013, 122, 1814-1814.	0.6	0
40	HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. <i>Journal of Clinical Oncology</i> , 2012, 30, 4111-4116.	0.8	145
41	Guidelines on the investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 446-467.	1.2	58
42	Rituximab and thalidomide combination therapy for Castleman disease. <i>British Journal of Haematology</i> , 2012, 158, 421-423.	1.2	25
43	An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK. <i>Value in Health</i> , 2010, 13, 346-357.	0.1	33
44	Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines. <i>British Journal of Haematology</i> , 2010, 149, 693-705.	1.2	191
45	Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4579-4586.	0.8	555
46	The therapeutic use of rituximab in non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2007, 78, 5-14.	1.1	3
47	Should you tell patients about beneficial treatments that they cannot have? Yes. <i>BMJ: British Medical Journal</i> , 2007, 334, 826-826.	2.4	12
48	Pathogenesis of MALT lymphoma: Implications for risk stratification and therapy. <i>Leukemia and Lymphoma</i> , 2007, 48, 2087-2088.	0.6	1
49	The therapeutic use of rituximab in non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2007, 78, 5-14.	1.1	84
50	Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1590-1596.	0.8	73
51	A Randomised, Double-Blind, Placebo Controlled, Multicentre Trial of ATL-104, a Swallowable Mouthwash, in Patients with Oral Mucositis Following Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i> , 2006, 108, 45-45.	0.6	12
52	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. <i>Blood</i> , 2005, 105, 1417-1423.	0.6	896
53	Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 155-167.	2.0	381
54	Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2005, 32, 36-43.	0.8	35

#	ARTICLE	IF	CITATIONS
55	Monoclonal antibody therapy for lymphoma. Blood Reviews, 2003, 17, 143-152.	2.8	34
56	Current Treatment Options in Aggressive Lymphoma. Leukemia and Lymphoma, 2003, 44, S15-S27.	0.6	21
57	Follicular lymphoma. , 2001, , 111-125.		0
58	Lymphoma in the immunosuppressed. , 2001, , 252-265.		0
59	Graft-versus-host disease in solid organ transplantation. Transplant International, 1991, 4, 67-71.	0.8	34
60	Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. Leukemia and Lymphoma, 1990, 2, 179-193.	0.6	67
61	Epidemiology of myeloma. , 0, , 1-10.		0
62	Imaging of myeloma. , 0, , 28-38.		0
63	Cell cycle regulation and myeloma precursor cells. , 0, , 39-47.		0
64	The genetic and epigenetic mechanisms underlying the behavior of myeloma. , 0, , 48-63.		0
65	The myeloma bone marrow environment and survival signaling. , 0, , 64-83.		0
66	Immune dysfunction in multiple myeloma. , 0, , 84-95.		0
67	Myeloma bone disease " pathogenesis of bone destruction and therapeutic strategies. , 0, , 96-109.		0
68	Principles of pathway directed therapy. , 0, , 110-120.		0
69	Multiple myeloma: management of de novo disease to include HDT. , 0, , 134-143.		0
70	Treatment of relapsed/refractory myeloma. , 0, , 144-166.		0
71	Solitary bone and extra-medullary plasmacytoma. , 0, , 167-173.		1
72	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 190-215.		0

#	ARTICLE	IF	CITATIONS
73	Treatment of emergent peripheral neuropathy in plasma cell disorders. , 0 , 245-254.		0
74	The management of infection in myeloma. , 0 , 276-287.		0
75	Diagnosis of myeloma and related plasma cell disorders. , 0 , 11-27.		0
76	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0 , 121-133.		2
77	Castlemanâ€™s disease. , 0 , 216-224.		0
78	POEMS syndrome and paraproteinemic syndromes: management and follow-up. , 0 , 225-244.		0
79	Management of renal failure in multiple myeloma. , 0 , 255-275.		0
80	Follicular lymphoma. , 0 , 87-103.		0
81	Lymphoma in the immunosuppressed. , 0 , 273-285.		0